Reuters logo
BRIEF-Spark Therapeutics gets rare pediatric disease designation for its investigational treatment from FDA
July 20, 2017 / 12:26 PM / 3 months ago

BRIEF-Spark Therapeutics gets rare pediatric disease designation for its investigational treatment from FDA

July 20 (Reuters) - Spark Therapeutics Inc

* Spark Therapeutics receives rare pediatric disease designation for investigational LUXTURNA (voretigene neparvovec) from FDA

* Spark Therapeutics Inc- ‍Prescription Drug User Fee Act (PDUFA) action date of Jan 12, 2018 for LUXTURNA​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below